The Board of Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) has decided to further extend the closing date of the share purchase plan (SPP) due to the Elanco Agreement announcement made today.
Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced the signing of a collaborative research, license and commercialisation agreement with Elanco, the animal health division of US pharmaceutical company Eli Lilly and Company (NYSE:LLY).
Leading developer of RNA interference (RNAi)-based therapeutics Benitec Limited (ASX:BLT)(PINK:BNIKF) announced today that Dr John Zaia had presented an update on City of Hope's HIV human stem cell study at an international conference in San Diego, USA.
Benitec Limited (ASX:BLT)(PINK:BNIKF) is pleased to announce that the US Patent and Trademark Office ("USPTO") has recently withdrawn its novelty objection to Benitec's seminal RNAi interference US patent 6,573,099, often referred to as the "Graham" patent. This patent has been undergoing re-examination as outlined in previous announcements.
To ensure that you remain well informed of our remarkable progress, as your Chairman, I will be providing you with regular updates outlining Mesoblast's key near-term objectives and major highlights. Following our first quarter results, I thought it opportune to provide you with my first of planned regular communications.
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) notes that GlaxoSmithKline (GSK) has announced important initiatives to assist governments and health authorities around the world to respond to the emergence of the new influenza A (H1N1) strain (previously referred to as Swine Flu).
Australian regenerative medicine company, Mesoblast Limited (ASX:MSB(PINK:MBLTY), today announced it has received approval at Melbourne's Epworth hospital to commence a Phase 2 trial of its allogeneic, or "off-the-shelf", cell therapy product for fusion of the cervical spine.
